Cargando…

Expression and prognostic relevance of MET and phospho-BAD in non-small cell lung cancer

BACKGROUND: MET is involved in the progression of several types of human cancers, while phospho-BAD(Ser-136) is a key molecule in apoptosis and might be regulated by MET. The aim of this study was to investigate the correlation between altered expression of MET and phospho-BAD in non-small cell lung...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Wenze, Ai, Ting, Gao, Ying, Zhang, Yingbing, Cui, Jie, Song, Liping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2013
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3787924/ https://www.ncbi.nlm.nih.gov/pubmed/24092988 http://dx.doi.org/10.2147/OTT.S50428

Ejemplares similares

Prognostic value of MET, cyclin D1 and MET gene copy number in non-small cell lung cancer
por: Sun, Wenze, et al.
Publicado: (2013)

Profiling of Phospho-AKT, Phospho-mTOR, Phospho-MAPK and EGFR in Non-small Cell Lung Cancer
por: Kitano, Haruhisa, et al.
Publicado: (2014)

Chlorogenic acid alleviates the reduction of Akt and Bad phosphorylation and of phospho-Bad and 14-3-3 binding in an animal model of stroke
por: Shah, Murad-Ali, et al.
Publicado: (2022)

Pristimerin enhances the effect of cisplatin by inhibiting the miR-23a/Akt/GSK3β signaling pathway and suppressing autophagy in lung cancer cells
por: Zhang, Yingbing, et al.
Publicado: (2019)

Expression and prognostic relevance of MAGE-A3 and MAGE-C2 in non-small cell lung cancer
por: Chen, Xinfeng, et al.
Publicado: (2017)

MYSM1 induces apoptosis and sensitizes TNBC cells to cisplatin via RSK3–phospho-BAD pathway
por: Guan, Xiaolin, et al.
Publicado: (2022)

Multiplex RNA‐based detection of clinically relevant MET alterations in advanced non‐small cell lung cancer
por: Aguado, Cristina, et al.
Publicado: (2020)

miR-30a radiosensitizes non-small cell lung cancer by targeting ATF1 that is involved in the phosphorylation of ATM
por: Guo, Yuyan, et al.
Publicado: (2017)

Meeting an un-MET need: Targeting MET in non-small cell lung cancer
por: Michaels, Elena, et al.
Publicado: (2022)

The Prognostic Role of MET Protein Expression Among Surgically Resected Non-small Cell Lung Cancer Patients: A Meta-Analysis
por: Ma, Guangzhi, et al.
Publicado: (2019)

MET and Small-Cell Lung Cancer
por: Gelsomino, Francesco, et al.
Publicado: (2014)

MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer
por: Ramesh, Shrey, et al.
Publicado: (2023)

Detection of MET Polysomy by Next-generation Sequencing and Its Clinical Relevance for MET Inhibitors
por: Sun, Boyang, et al.
Publicado: (2023)

MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors
por: Peng, Lun-Xi, et al.
Publicado: (2021)

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis
por: Liang, Hongge, et al.
Publicado: (2020)

Prognostic value of MET copy number gain in non-small-cell lung cancer: an updated meta-analysis
por: Kim, Jung Han, et al.
Publicado: (2018)

Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
por: Kim, Seulki, et al.
Publicado: (2019)

Prognostic Significance of Nuclear Phospho-ATM Expression in Melanoma
por: Bhandaru, Madhuri, et al.
Publicado: (2015)

MET Inhibitor is Expected to Overcome MET Amplification-Induced Immunotherapy Resistance in Non-Small Cell Lung Cancer
por: Ruan, Ji
Publicado: (2021)

Clinicopathological characteristics of Non-Small Cell Lung Cancer (NSCLC) patients with c-MET exon 14 skipping mutation, MET overexpression and amplification
por: Ding, Caixia, et al.
Publicado: (2023)

Management of Peripheral Edema in Patients with MET Exon 14-Mutated Non-small Cell Lung Cancer Treated with Small Molecule MET Inhibitors
por: Nishio, Makoto, et al.
Publicado: (2022)

A narrative review of MET inhibitors in non-small cell lung cancer with MET exon 14 skipping mutations
por: Santarpia, Mariacarmela, et al.
Publicado: (2021)

Direct bilirubin levels are prognostic in non-small cell lung cancer
por: Song, Ying-Jian, et al.
Publicado: (2017)

Expression of c‐met/HGF Receptor in Human Non‐small Cell Lung Carcinomas in vitro and in vivo and Its Prognostic Significance
por: Ichimura, Eiji, et al.
Publicado: (1996)

Prognostic and therapeutic relevance of FLIP and procaspase-8 overexpression in non-small cell lung cancer
por: Riley, J S, et al.
Publicado: (2013)

miR‐200c and phospho‐AKT as prognostic factors and mediators of osteosarcoma progression and lung metastasis
por: Berlanga, Pablo, et al.
Publicado: (2016)

MEK inhibitors against MET-amplified non-small cell lung cancer
por: Chiba, Masato, et al.
Publicado: (2016)

Met is involved in TIGAR-regulated metastasis of non-small-cell lung cancer
por: Shen, Mengqin, et al.
Publicado: (2018)

MET immunochemistry: a reliable screening tool for MET exon 14 skipping mutations in non-small cell lung cancer?
por: Pruis, Melinda A., et al.
Publicado: (2020)

Effective response to crizotinib of concurrent KIF5B-MET and MET-CDR2-rearranged non-small cell lung cancer: A case report
por: Liu, Lian-Fang, et al.
Publicado: (2022)

Correlation among genetic variations of c-MET in Chinese patients with non-small cell lung cancer
por: Duan, Jianchun, et al.
Publicado: (2017)

Detection of necroptosis by phospho-MLKL immunohistochemical labeling
por: He, Peng, et al.
Publicado: (2020)

MET overexpression, gene amplification and relevant clinicopathological features in gastric adenocarcinoma
por: Zhang, Jing, et al.
Publicado: (2016)

HGF/MET and the Immune System: Relevance for Cancer Immunotherapy
por: Papaccio, Federica, et al.
Publicado: (2018)

Differential responsiveness of MET inhibition in non-small-cell lung cancer with altered CBL
por: Tan, Yi-Hung Carol, et al.
Publicado: (2017)

Targeting the MET-Signaling Pathway in Non-Small–Cell Lung Cancer: Evidence to Date
por: Bylicki, Olivier, et al.
Publicado: (2020)

The Role of MET Inhibitor Therapies in the Treatment of Advanced Non-Small Cell Lung Cancer
por: De Mello, Ramon Andrade, et al.
Publicado: (2020)

Savolitinib versus crizotinib for treating MET positive non‐small cell lung cancer
por: Miao, Kang, et al.
Publicado: (2023)

The prognostic role of a phospho-Stathmin 1 signature in breast cancer treated with neoadjuvant chemotherapy
por: Xie, Zhen, et al.
Publicado: (2022)

MET exon 14 skipping defines a unique molecular class of non-small cell lung cancer
por: Zheng, Difan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_v9t1lhjktak50gigqeg9nfou65